A short review of the plant to product journey.

1. Plant to product – some
thoughts
David G. Elliott
B.A. (Lon) MBA Executive
Management (Hull) MCIM

2. Brand Owners in the Doldrums?
• Pressure from retailers restricts R&D.
• Without exciting products de-listing an ever
present threat.
• R&D typically 1% (Pharma 18%) of sales.
• Need to improve quantum and quality of R&D.
• Open Innovation – P&G, Reckitt Benckiser etc.

3. Complex.
Value Chains

4. What does this mean?
• Can be a long journey.
• Need for evidence – trials, human studies etc.
• Supply should not be in one Company ideally.
• Some ideas more market ready than others.
• Skin care may be point of entry.
• Stamina needed.

5. Some examples
Sativex® is a cannabinoid medicine for the
treatment of spasticity due to multiple sclerosis
which is also in development in cancer pain and
neuropathic pain of various origins..
Registered in 25 countries for MS.

6. Some examples
• Nivea • Sea buckthorn

7. Some examples
• Traditional.
• Mature.
• Well known.

8. Some examples
• Gaviscon • Long history.
• Many variants
• CE mark if
launched today?

9. Some examples
• US Product • Role in diabetes
foot care?

10. Must be ‘World Class’
• Must offer significant added value – unmet
need.
• Some ground breaking innovations will not
prove successful.
• World wide potential demands ability to scale
up.
• Open Innovation/Partnerships etc.

11. The Future
• Innovation likely to come from SMEs with links
to big Corporate via Open Innovation networks.
• The big will get stronger leveraging brand
power across multiple markets.
• May be need to use OI intermediaries etc.
• Crowd funding?
• Protein from algae?

12. Thank you
• Questions?